IRIS
MASSIMINO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.120
EU - Europa 1.872
AS - Asia 1.224
SA - Sud America 386
AF - Africa 259
OC - Oceania 2
Totale 6.863
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.028
IT - Italia 771
SG - Singapore 646
BR - Brasile 358
IE - Irlanda 334
CN - Cina 313
UA - Ucraina 218
CI - Costa d'Avorio 155
DE - Germania 131
IN - India 126
BE - Belgio 90
CA - Canada 87
NL - Olanda 78
SN - Senegal 74
RU - Federazione Russa 69
VN - Vietnam 40
FI - Finlandia 37
GB - Regno Unito 35
SE - Svezia 25
BD - Bangladesh 18
FR - Francia 14
UZ - Uzbekistan 14
CZ - Repubblica Ceca 13
AR - Argentina 12
CH - Svizzera 12
KR - Corea 12
NG - Nigeria 12
GR - Grecia 11
PL - Polonia 10
TR - Turchia 10
IL - Israele 6
IQ - Iraq 6
IR - Iran 6
MA - Marocco 6
AT - Austria 5
EC - Ecuador 5
JP - Giappone 5
TN - Tunisia 5
BG - Bulgaria 4
CO - Colombia 4
ES - Italia 4
HK - Hong Kong 4
MX - Messico 4
NO - Norvegia 4
AE - Emirati Arabi Uniti 3
KE - Kenya 3
LB - Libano 3
RS - Serbia 3
SA - Arabia Saudita 3
AU - Australia 2
AZ - Azerbaigian 2
EG - Egitto 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
VE - Venezuela 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
GA - Gabon 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
NI - Nicaragua 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 6.863
Salva come PNG Salva come JPEG
Città #
Santa Clara 721
Chandler 443
Singapore 413
Dublin 334
Chicago 280
Jacksonville 219
Catania 196
Abidjan 155
Boardman 124
Kochi 104
Cambridge 93
Ashburn 92
Lawrence 91
Andover 87
Nanjing 82
Dakar 74
Grafing 64
Civitanova Marche 59
Toronto 59
Rotterdam 53
Wingene 50
Des Moines 48
Wilmington 44
San Mateo 43
Palermo 33
Munich 30
New York 29
Dong Ket 27
Milan 27
Los Angeles 26
São Paulo 25
Brussels 24
Hefei 24
The Dalles 23
Turku 22
Columbus 21
Ottawa 19
Rome 19
Beijing 17
Hebei 17
Nanchang 17
Shenyang 17
Jiaxing 16
Seattle 16
Council Bluffs 15
Falls Church 15
Saint Petersburg 15
Bari 14
Aci Catena 13
Changsha 13
Abuja 12
Belo Horizonte 12
Bremen 12
Hanoi 12
Messina 12
Rio de Janeiro 12
Santa Venerina 12
Brno 11
Nijmegen 11
Seoul 11
Brasília 10
Helsinki 9
Izegem 9
Pune 9
Tianjin 9
Curitiba 8
Dhaka 8
Redmond 8
San Giovanni la Punta 8
Mascalucia 7
San Francisco 7
Washington 7
Acireale 6
Bernareggio 6
Lappeenranta 6
Leawood 6
Manaus 6
Moscow 6
Paternò 6
Phoenix 6
Portland 6
Reggio Emilia 6
Fantina 5
Giardini-Naxos 5
Guangzhou 5
Hanover 5
Mazzarino 5
Milazzo 5
Montreal 5
Norwalk 5
Tashkent 5
Tokyo 5
Ardabil 4
Augusta 4
Comiso 4
Edinburgh 4
Florence 4
Frankfurt am Main 4
Grammichele 4
Guarulhos 4
Totale 4.820
Salva come PNG Salva come JPEG
Nome #
Novel mechanisms of tumor promotion by the insulin receptor isoform a in triple-negative breast cancer cells 191
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 155
A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications 117
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 115
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release 110
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily 109
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop 104
Activation of the IGF axis in thyroid cancer: Implications for tumorigenesis and treatment 104
Diagnostic utility of the immunohistochemical expression of serin and arginine rich splicing factor 1 (Srsf1) in the differential diagnosis of adult gliomas 104
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 98
Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series 91
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 91
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice 90
Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells 89
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 89
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 88
B-ALL relapses after autologous stem cell transplantation associated with a shift from e1a2 to e14a2 BCR-ABL transcripts: A case report 88
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND FUNCTION OF INTERFERON REGULATORY FACTOR 5 (IRF-5) IN CHRONIC MYELOID LEUKEMIA CELLS 87
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 87
Comparative proteomic analysis of insulin receptor isoform A and B signaling 86
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 86
New insights in thyroid cancer and p53 family proteins 85
Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells.Cancer Res 84
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 84
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 84
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 83
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 81
BCR-Abl tyrosine kinase activity modulates the expression of Interferon Regulatory Factor-5 in CML cells 81
BCR-ABL tyrosine kinase activity modulates the phosphorylation and the localization of Interferon Regulatory Factor 5 (IRF-5)in Chronic Myeloid Leukemia cells 81
A novel and selective sigma-1/2 receptor ligand (PO680C): Binding properties and expression of tissue transglutaminase 80
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells 80
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22) 80
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience 80
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 79
Uncommon long-term survival in a patient with chronic myeloid leukemia 79
Computational and Experimental Characterization of Two Nuclear Localization Signals and a Nuclear Export Signal that modulate BCR intracellular localization 79
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 79
BCR-ABL TYROSINE KINASE ACTIVITY MODULATES THE PHOSPHORYLATION, LOCALIZATION AND BIOLOGICAL FUNCTION OF INTERFERON REGULATORY FACTOR 5 IN CHRONIC MYELOID LEUKEMIA CELLS 78
Insulin receptor isoforms differently regulate cell proliferation and apoptosis in the ligand‐occupied and unoccupied state 76
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 76
c-IAP1, Survivin and Smac contribute to chemotherapy resistance in undifferentiated thyroid cancer cells 75
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 75
Successful management of a pregnant patient with chronic myeloid leukemia receiving standard dose imatinib 74
Combined inhibition of bcl2 and bcr-abl1 exercises anti-leukemia activity but does not eradicate the primitive leukemic cells 74
A novel and selective σ1/2 receptor ligand (PO680C): binding properties and expression of tissue transglutaminase 72
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. 72
Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias 71
Detection and clinical implications of a novel BCR-ABL1 E12A2 insertion/deletion in a CML patient expressing the E13A2 isoform 70
Opportunities and challenges of liquid biopsy in thyroid cancer 69
FLAIRectomy in Supramarginal Resection of Glioblastoma Correlates With Clinical Outcome and Survival Analysis: A Prospective, Single Institution, Case Series 69
Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far 68
UNA INSERZIONE NEL DOMINIO TIROSIN-CHINASICO DI BCR-ABL POTREBBE CONTRIBUIRE ALLA RESISTENZA AD IMATINIB MESILATO DI PAZIENTI AFFETTI DA LEUCEMIA MIELOIDE CRONICA 68
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma 68
Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity 68
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase 63
Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells 63
Espressione e funzione di OMI/HTRA2 in tumori solidi ed ematologici 62
Rapid decline of philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report 62
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors 61
BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy 61
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 61
Novel methyl-2-[4-[(4-hydroxy-4-phenylpiperidin-1-yl)methyl]-1-phenylcyclopropane-carboxylate derivatives as sigma-1 and sigma-2 receptor ligands 60
Ruolo delle IAPs e di Smac/DIABLO nella resistenza ai farmaci antiblastici di cellule di carcinoma indifferenziato della tiroide 60
High BCR-ABL/GUS(IS) Levels at Diagnosis Are Associated with Unfavorable Responses to Standard Dose Imatinib 59
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia 58
UNFAVOURABLE OUTCOME OF CML PATIENTS CARRYING COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS TREATED WITH TYROSINE KINASE INHIBITORS 58
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer 57
Diagnosis of Chronic Myeloid Leukemia Early in Pregnancy 57
Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma 57
High BCR-ABL expression levels at diagnosis may predict unfavorable CML responses to Imatinib therapy 55
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia 53
Sustained Responses and Resistance to Imatinib Mesylate in the First 173 Chronic Myeloid Leukemia Patients Accrued by the SCREEN Multicenter Study: First Interim Report 53
Experimental and Computational Characterization of Amino Acidic Residues in the BCR-ABL kinase domain contributing to TKI resistance in patients with Chronic Myeloid Leukemia 52
EFFICACY OF IMATINIB MESYLATE ON CHRONIC PHASE CML PATIENTS ACCRUED IN THE SCREEN MULTICENTER STUDY: INTERIM REPORT ON THE FIRST 193 CASES 52
Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines 51
L’attività tirosin-chinasica di BCR/Abl modula l’espressione di IRF-5 51
HIGH BCR-ABL LEVELS AT DIAGNOSIS ARE ASSOCIATED WITH UNFAVORABLE RESPONS- ES TO IMATINIB 51
High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib 50
Computational and biological characterization of nuclear import/export signals of the human BCR protein 50
THE SCREEN PROJECT: A CML DATA REGISTRY IN SICILY AND CALABRIA 49
Computational and experimental characterization of critical amino acidic residues in the BCR-ABL kinase domain explaining TKIs resistance in patients with chronic myeloid leukemia 49
SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR σ1 RECEPTOR 49
The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy 49
High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability 47
IRF5 promotes the proliferation of human thyroid cancer cells. 46
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis 46
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance 44
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain 43
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor 41
High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib 41
RAPID RESPONSE TO DASATINIB IN A CML BLAST CRISIS PATIENT THAT SUBSEQUENTLY DEVELOPED SEQUENTIAL BCR-ABL MUTATIONS CAUSING MULTI-DRUG RESISTANCE: A CASE REPORT 40
Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells 40
An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma 40
Molecular dynamics simulations reveal the role of five BCR-ABL kinase domain critical residues in TKIS binding 39
SINTESI E VALUTAZIONE FARMACOLOGICA DI DERIVATI METIL 2-[(4-BENZILPIPERIDIN-1-IL)METIL]-1-FENIL-CICLOPROPANCARBOSSILATO COME LIGANDI SIGMA AD ALTA AFFINITÀ 37
Computational and Experimental Characterization of Critical Amino Acid Residues in the BCR-ABL Kinase Domain Explaining Imatinib Resistance in Patients with Chronic Myeloid Leukemia 35
HIGH DOSE IMATINIB TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE AND COMPLETE CYTOGENETIC RESPONSE: IS IT WORTHWHILE? 34
TOWARDS A NEED IN OPTIMIZING CML MANAGEMENT IN SUBOPTIMAL RESPONDERS: DATA FROM THE SCREEN REGISTRY 34
In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients 33
REThinking the role of the RET oncogene in breast cancer 32
Totale 6.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.822
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.822
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021539 19 37 48 11 128 16 51 3 106 4 68 48
2021/2022686 54 97 15 9 112 13 103 27 52 14 35 155
2022/20231.373 106 102 43 153 91 214 19 263 289 11 50 32
2023/2024766 57 107 30 36 32 184 11 44 7 35 133 90
2024/20252.956 111 445 116 175 585 394 191 80 187 203 315 154
2025/2026128 128 0 0 0 0 0 0 0 0 0 0 0
Totale 7.057